Novation signs on Oncura as second brachytherapy supplier:
This article was originally published in Clinica
Oncura, the Plymouth Meeting, Pennsylvania-based prostate cancer treatment company, has won a three-year deal to supply US group purchasing organisation Novation with its portfolio of Iodine-125 and Palladium-103 prostate brachytherapy products. The agreement takes effect immediately. Novation has also taken on Chatsworth, California-based North American Scientific as its brachytherapy products supplier (see Clinica No 1207, p 18).
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.